Long‐term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
: Aims. To assess the efficacy and long‐term effects of glipizide treatment on glucose and insulin metabolism in individuals with impaired glucose tolerance (IGT). Methods. Thirty‐seven first‐degree relatives of patients with type 2 diabetes fulfilling WHO criteria for IGT were randomized to treatment with either glipizide 2.5 mg once daily or matching placebo for 6 months. A 75 g, 2‐h oral (OGTT) and 60 min intravenous glucose tolerance test (IVGTT) were performed at baseline and after 6 months. The subjects were followed up for another 12 months after discontinuation of treatment and a repeat OGTT was performed at 18 months. Results. Thirty‐three subjects fulfilled the study. Markers of insulin sensitivity – i.e. fasting insulin and HOMA IR‐index – improved in the glipizide group (P = 0.04 and 0.02 respectively) as well as HDL cholesterol (P = 0.05) compared with placebo group after 6 months. At 18 months, both fasting and 2 h glucose concentrations were significantly lower in the glipizide group compared with the placebo group (P = 0.04 and 0.03 respectively). The prevalence of type 2 diabetes was 29.4% in the placebo group and 5.9% in the glipizide group at 18 months. This equals an 80% relative risk reduction in the active treatment group. Conclusions. Short‐term treatment with glipizide improves glucose and insulin metabolism in subjects with IGT primarily by improving insulin sensitivity mediated by lowering glucose toxicity, thereby providing the beta cells rest. Larger studies are needed to establish whether these effects are sufficient to prevent progression to manifest type 2 diabetes and associated cardiovascular morbidity in subjects at increased risk of developing type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Self-citationLillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Warram, J. H., Martin, B. C., Krolewski, A. S., Soeldner, J. S., & Kahn, C. R. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-909 · Cited by 1,038
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Self-citation(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
Cited by
A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes
Paulweber, B., Valensi, P., Lindström, J., Lalic, N., Greaves, C., McKee, M., Kissimova-Skarbek, K., Liatis, S., Cosson, E., Szendroedi, J., et al. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0029-1240928 · Cited by 469
Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0034-6 · Cited by 403
Haw, J. S., Galaviz, K. I., Straus, A. N., Kowalski, A. J., Magee, M. J., Weber, M. B., Wei, J., Narayan, K. M. V., & Ali, M. K. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6040 · Cited by 354
“62) (Figure 3).(33,44,55-73) Insulin sensitizers (metformin, rosiglitazone, and pioglitazone) achieved an RR reduction of 53% (RR, 0.”
BackgroundGillies, C. L., Lambert, P. C., Abrams, K. R., Sutton, A. J., Cooper, N. J., Hsu, R. T., Davies, M. J., & Khunti, K. (2008) · BMJ · doi:10.1136/bmj.39545.585289.25 · Cited by 290
Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis
Galaviz, K. I., Weber, M. B., Suvada, K., Gujral, U. P., Wei, J., Merchant, R., Dharanendra, S., Haw, J. S., Narayan, K. M. V., & Ali, M. K. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.10.020 · Cited by 149
Metadata
- Authors
- ERIKSSON, J. G., LEHTOVIRTA, M., EHRNSTRÖM, B., SALMELA, S., & GROOP, L.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2006-03-24
- Volume
- 259
- Issue
- 6
- Pages
- 553-560
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1983130632
- Cited by
- 29
- References
- 6
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. https://app.cochat.ai/papers/10.1111/j.1365-2796.2006.01633.x
- The paper
- ERIKSSON, J. G., LEHTOVIRTA, M., EHRNSTRÖM, B., SALMELA, S., & GROOP, L. (2006). Long‐term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2006.01633.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.